New drug MIB-725 gets first safety check in healthy volunteers
NCT ID NCT06815991
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called MIB-725 in 32 healthy adults aged 19 to 60. Participants receive a single dose (100 to 800 mg) and are monitored for side effects and how the drug moves through the body. The goal is to see if the drug is safe before testing it in people with a disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breakfast or fast? a trial puts Prifetrastat's absorption to the test
- Magic mushroom compound may rewire Self-Awareness — scientists put it to the test
- Can a phone app ease caregiver burnout? new study tests digital therapy
- Robotic hip brace may help control blood sugar after eating
- Smart knee brace and AI could revolutionize home rehab for arthritis
- Training the brain to hear and fix speech errors